File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong

TitleComparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong
Authors
KeywordsAnti-diabetic medication
Depression
DPP4 inhibitor
SGLT2 inhibitor
Type 2 diabetes
Issue Date2023
Citation
Acta Diabetologica, 2023, v. 60, n. 7, p. 917-927 How to Cite?
AbstractIntroduction: The risk of new onset depression associated with sodium-glucose co-transporter 2 inhibitor (SGLT2I) use in patients with type 2 diabetes mellitus (T2DM) remains unclear. This study investigated the risk of new onset depression between SGLT2I and dipeptidyl peptidase 4 inhibitor (DPP4I) users. Methods: This was a population-based cohort study of T2DM patients in Hong Kong between January 1st, 2015, and December 31st, 2019. T2DM patients over 18 with either SGLT2I or DPP4I use were included. 1:1 propensity-score matching using the nearest-neighbour method was conducted based on demographics, past comorbidities and non-DPP4I/SGLT2I medication use. Cox regression analysis models were used to identify significant predictors for new onset depression. Results: The study cohort included a total of 18,309 SGLT2I users and 37,269 DPP4I users (55.57% male, mean age: 63.5 ± 12.9 years) with a median follow-up duration of 5.56 (IQR: 5.23–5.8) years. After propensity score matching, SGLT2I use was associated with a lower risk of new onset depression compared to DPP4I use (HR: 0.52, 95% CI: [0.35, 0.77], P = 0.0011). These findings were confirmed by Cox multivariable analysis and sensitive analyses. Conclusion: SGLT2I use is associated with significantly lower risk of depression compared to DPP4 use in T2DM patients using propensity score matching and Cox regression analyses.
Persistent Identifierhttp://hdl.handle.net/10722/336900
ISSN
2023 Impact Factor: 3.1
2023 SCImago Journal Rankings: 0.980
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMui, Jonathan V.-
dc.contributor.authorLi, Lifang-
dc.contributor.authorChou, Oscar Hou In-
dc.contributor.authorAzfar, Nida-
dc.contributor.authorLee, Athena-
dc.contributor.authorHui, Jeremy-
dc.contributor.authorLee, Sharen-
dc.contributor.authorTse, Gary-
dc.contributor.authorZhou, Jiandong-
dc.date.accessioned2024-02-29T06:57:18Z-
dc.date.available2024-02-29T06:57:18Z-
dc.date.issued2023-
dc.identifier.citationActa Diabetologica, 2023, v. 60, n. 7, p. 917-927-
dc.identifier.issn0940-5429-
dc.identifier.urihttp://hdl.handle.net/10722/336900-
dc.description.abstractIntroduction: The risk of new onset depression associated with sodium-glucose co-transporter 2 inhibitor (SGLT2I) use in patients with type 2 diabetes mellitus (T2DM) remains unclear. This study investigated the risk of new onset depression between SGLT2I and dipeptidyl peptidase 4 inhibitor (DPP4I) users. Methods: This was a population-based cohort study of T2DM patients in Hong Kong between January 1st, 2015, and December 31st, 2019. T2DM patients over 18 with either SGLT2I or DPP4I use were included. 1:1 propensity-score matching using the nearest-neighbour method was conducted based on demographics, past comorbidities and non-DPP4I/SGLT2I medication use. Cox regression analysis models were used to identify significant predictors for new onset depression. Results: The study cohort included a total of 18,309 SGLT2I users and 37,269 DPP4I users (55.57% male, mean age: 63.5 ± 12.9 years) with a median follow-up duration of 5.56 (IQR: 5.23–5.8) years. After propensity score matching, SGLT2I use was associated with a lower risk of new onset depression compared to DPP4I use (HR: 0.52, 95% CI: [0.35, 0.77], P = 0.0011). These findings were confirmed by Cox multivariable analysis and sensitive analyses. Conclusion: SGLT2I use is associated with significantly lower risk of depression compared to DPP4 use in T2DM patients using propensity score matching and Cox regression analyses.-
dc.languageeng-
dc.relation.ispartofActa Diabetologica-
dc.subjectAnti-diabetic medication-
dc.subjectDepression-
dc.subjectDPP4 inhibitor-
dc.subjectSGLT2 inhibitor-
dc.subjectType 2 diabetes-
dc.titleComparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00592-023-02063-6-
dc.identifier.pmid37000300-
dc.identifier.scopuseid_2-s2.0-85151444021-
dc.identifier.volume60-
dc.identifier.issue7-
dc.identifier.spage917-
dc.identifier.epage927-
dc.identifier.eissn1432-5233-
dc.identifier.isiWOS:000961193700002-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats